BridgeBio disclosed positive top-line results from Propel 3, a global Phase 3 trial testing oral infigratinib in children with achondroplasia. Infigratinib demonstrated a statistically significant increase in annualized height velocity versus placebo, with treatment differences reported at +1.74 to +2.10 cm/year depending on the analysis. The company said regulatory submissions are planned for later this year. BridgeBio positioned the oral FGFR3 inhibitor as a potential alternative to existing injectable therapies; the study reported a tolerable safety profile with a small number of transient, asymptomatic phosphate elevations. The result adds to a run of late‑stage wins for BridgeBio and sets up a competitive market dynamic with BioMarin and Ascendis. Sources: BridgeBio press release, Propel 3 topline data.